Preclinical Evaluation of a Novel High-Affinity Radioligand [ 99mTc]Tc-BQ0413 Targeting Prostate-Specific Membrane Antigen (PSMA); International Journal of Molecular Sciences; Vol. 24 - iss.24
| Parent link: | International Journal of Molecular Sciences.— .— Basel: MDPI AG Vol. 24 - iss.24.— 2023.— Article number 17391, 24p. |
|---|---|
| Rannpháirtithe: | Bezverkhniaia E. A. Ekaterina Aleksandrovna, Kanellopoulos P. Panagiotis, Abouzayed A. Ayman, Larkina M. S. Mariya Sergeevna, Oroujeni M. Maryam, Vorobjeva (Vorobyeva) A. G. Anzhelika Grigorjevna, Rosenstrom U. Ulrika, Tolmachev V. M. Vladimir Maksimilianovich, Orlova A. M. Anna Markovna |
| Achoimre: | Radionuclide imaging using radiolabeled inhibitors of prostate-specific membrane antigen (PSMA) can be used for the staging of prostate cancer. Previously, we optimized the Glu-urea-Lys binding moiety using a linker structure containing 2-napththyl-L-alanine and L-tyrosine. We have now designed a molecule that contains mercaptoacetyl–triglutamate chelator for labeling with Tc99m (designated as BQ0413). The purpose of this study was to evaluate the imaging properties of [99mTc]Tc-BQ0413. PSMA-transfected PC3-pip cells were used to evaluate the specificity and affinity of [99mTc]Tc-BQ0413 binding in vitro. PC3-pip tumor-bearing BALB/C nu/nu mice were used as an in vivo model. [99mTc]Tc-BQ0413 bound specifically to PC3-pip cells with an affinity of 33 ± 15 pM. In tumor-bearing mice, the tumor uptake of [99mTc]Tc-BQ0413 (38 ± 6 %IA/g in PC3-pip 3 h after the injection of 40 pmol) was dependent on PSMA expression (3 ± 2 %IA/g and 0.9 ± 0.3 %IA/g in PSMA-negative PC-3 and SKOV-3 tumors, respectively). We show that both unlabeled BQ0413 and the commonly used binder PSMA-11 enable the blocking of [99mTc]Tc-BQ0413 uptake in normal PSMA-expressing tissues without blocking the uptake in tumors. This resulted in an appreciable increase in tumor-to-organ ratios. At the same injected mass (5 nmol), the use of BQ0413 was more efficient in suppressing renal uptake than the use of PSMA-11. In conclusion, [99mTc]Tc-BQ0413 is a promising probe for the visualization of PSMA-positive lesions using single-photon emission computed tomography (SPECT). Текстовый файл |
| Teanga: | Béarla |
| Foilsithe / Cruthaithe: |
2023
|
| Ábhair: | |
| Rochtain ar líne: | https://doi.org/10.3390/ijms242417391 http://apex.tpu.ru/ap/PUBLIKACIYA.ORIGINAL_PUBL1?p_image_id=113631&p_session_id=109393972742875 |
| Formáid: | Leictreonach Caibidil leabhair |
| KOHA link: | https://koha.lib.tpu.ru/cgi-bin/koha/opac-detail.pl?biblionumber=672736 |
Míreanna comhchosúla
Reduction of Negative Charge in Mercaptoacetyl-Based Chelators Influences the Biodistribution of Prostate-Specific Membrane Antigen-Targeting Pseudopeptides Labeled with Technetium-99m; ACS Pharmacology & Translational Science; Vol. 8, iss. 10
Foilsithe / Cruthaithe: (2025)
Foilsithe / Cruthaithe: (2025)
Synthesis and Preclinical Evaluation of Urea-Based Prostate-Specific Membrane Antigen-Targeted Conjugates Labeled with 177Lu; ACS Pharmacology & Translational Science; Vol. 7, iss. 5
Foilsithe / Cruthaithe: (2024)
Foilsithe / Cruthaithe: (2024)
Single-Photon Emission Computer Tomography Imaging of Prostate-Specific Membrane Antigen (PSMA) Expression in Prostate Cancer Patients Using a Novel Peptide-Based Probe [99mTc]Tc-BQ0413 with Picomolar Affinity to PSMA: A Phase I/II Clinical Study; ACS Pharmacology & Translational Science; Vol. 8, iss. 3
Foilsithe / Cruthaithe: (2025)
Foilsithe / Cruthaithe: (2025)
Synthesis, 123I-Radiolabeling Optimization, and Initial Preclinical Evaluation of Novel Urea-Based PSMA Inhibitors with a Tributylstannyl Prosthetic Group in Their Structures; International Journal of Molecular Sciences; Vol. 24, iss. 15
Foilsithe / Cruthaithe: (2023)
Foilsithe / Cruthaithe: (2023)
Heterodimeric Radiotracer Targeting PSMA and GRPR for Imaging of Prostate Cancer—Optimization of the Affinity towards PSMA by Linker Modification in Murine Model; Pharmaceutics; Vol. 12, iss. 7
Foilsithe / Cruthaithe: (2020)
Foilsithe / Cruthaithe: (2020)
The development of cyclotron‑based radiopharmaceuticals: a comprehensive review of 64Cu and 123I‑radiolabeled urea‑based small molecule PSMA ligands; Journal of Radioanalytical and Nuclear Chemistry; Vol. 332
Foilsithe / Cruthaithe: (2023)
Foilsithe / Cruthaithe: (2023)
Preclinical Evaluation of 99mTc-Labeled GRPR Antagonists maSSS/SES-PEG2-RM26 for Imaging of Prostate Cancer; Pharmaceutics; Vol. 13, iss. 2
Foilsithe / Cruthaithe: (2021)
Foilsithe / Cruthaithe: (2021)
Phase I Clinical Study with the GRPR-Antagonist [99mTc]Tc-DB8 for SPECT Imaging of Prostate Cancer: Does the Injected Peptide Mass Make a Difference?; Pharmaceutics; Vol. 17, iss. 10
Foilsithe / Cruthaithe: (2025)
Foilsithe / Cruthaithe: (2025)
Preclinical Evaluation of the Copper-64 Labeled GRPR-Antagonist RM26 in Comparison with the Cobalt-55 Labeled Counterpart for PET-Imaging of Prostate Cancer; Molecules; Vol. 25, iss. 24
Foilsithe / Cruthaithe: (2020)
Foilsithe / Cruthaithe: (2020)
66Ga-PET-imaging of GRPR-expression in prostate cancer: production and characterization of [66Ga]Ga-NOTA-PEG2-RM26; Scientific Reports; Vol. 11, iss. 1
Foilsithe / Cruthaithe: (2021)
Foilsithe / Cruthaithe: (2021)
Influence of SBRT fractionation on TCP and NTCP estimations for prostate cancer; Physica Medica; Vol. 62
Foilsithe / Cruthaithe: (2019)
Foilsithe / Cruthaithe: (2019)
Novel Chlorin with a HYNIC: Synthesis, 99mTc-Radiolabeling, and Initial Preclinical Evaluation; Molecules; Vol. 30, iss. 1
Foilsithe / Cruthaithe: (2025)
Foilsithe / Cruthaithe: (2025)
Feasibility of simultaneous integrated boost for high-dose treatment of high-risk prostate cancer; Сибирский онкологический журнал; Т. 22, № 3
Foilsithe / Cruthaithe: (2023)
Foilsithe / Cruthaithe: (2023)
Preclinical Evaluation of the GRPR-Targeting Antagonist RM26 Conjugated to the Albumin-Binding Domain for GRPR-Targeting Therapy of Cancer; Pharmaceutics; Vol. 12, iss. 10
Foilsithe / Cruthaithe: (2020)
Foilsithe / Cruthaithe: (2020)
Dosimetric and radiobiological comparison of simultaneous integrated boost and sequential boost of locally advanced cervical cancer; Physica Medica; Vol. 73
Foilsithe / Cruthaithe: (2020)
Foilsithe / Cruthaithe: (2020)
Direct Intra-Patient Comparison of Scaffold Protein-Based Tracers, [99mTc]Tc-ADAPT6 and [99mTc]Tc-(HE)3-G3, for Imaging of HER2-Positive Breast Cancer; Cancers; Vol. 15 - iss. 12
Foilsithe / Cruthaithe: (2023)
Foilsithe / Cruthaithe: (2023)
Development of an automated unit for extraction-chromatographic separation of the 99Mo/99m Tc generator couple; Radiochemistry; Vol. 56, iss. 2
Foilsithe / Cruthaithe: (2014)
Foilsithe / Cruthaithe: (2014)
Preclinical Evaluation of 99mTc-ZHER2:41071, a Second-Generation Affibody-Based HER2-Visualizing Imaging Probe with a Low Renal Uptake; International Journal of Molecular Sciences; Vol. 22, iss. 5
Foilsithe / Cruthaithe: (2021)
Foilsithe / Cruthaithe: (2021)
Radiolabeled Complex of Antimicrobial Peptides UBI29-41 and UBI18-35 Labeled with 99mTc for Differential Diagnosis of Bone Infection of the Limbs; Bulletin of Experimental Biology and Medicine; Vol. 170, iss. 4
Foilsithe / Cruthaithe: (2021)
Foilsithe / Cruthaithe: (2021)
Comparative Preclinical Evaluation of the Tumor-Targeting Properties of Radioiodine and Technetium-Labeled Designed Ankyrin Repeat Proteins for Imaging of Epidermal Growth Factor Receptor Expression in Malignant Tumors; International Journal of Molecular Sciences; Vol. 26, iss. 21
Foilsithe / Cruthaithe: (2025)
Foilsithe / Cruthaithe: (2025)
Evaluation of the Functional Suitability of Carboxylate Chlorin e6 Derivatives for Use in Radionuclide Diagnostics; Pharmaceutics; Vol. 18, iss. 1
Foilsithe / Cruthaithe: (2026)
Foilsithe / Cruthaithe: (2026)
Validation of an Analytical HPLC Method for a New Diagnostic Octreotide Derivative for Neuroendocrine Tumors; Pharmaceutical Chemistry Journal; Vol. 53, iss. 9
Foilsithe / Cruthaithe: (2019)
Foilsithe / Cruthaithe: (2019)
Разработка модели малогабаритного экстрактора с саморегулируемым уровнем границы раздела фаз для разделения пары 99Мо/99MТс; Известия Томского политехнического университета [Известия ТПУ]; Т. 323, № 3 : Химия
Foilsithe / Cruthaithe: (2013)
Foilsithe / Cruthaithe: (2013)
Cyclotron Production of 99Mo Radionuclide by Bombarding Zirconium Targets with Alpha Particle Beams; Russian Physics Journal; Vol. 62, iss. 4
Foilsithe / Cruthaithe: (2019)
Foilsithe / Cruthaithe: (2019)
Evaluation of affinity matured Affibody molecules for imaging of the immune checkpoint protein B7-H3; Nuclear Medicine and Biology; Vol. 124-125
Foilsithe / Cruthaithe: (2023)
Foilsithe / Cruthaithe: (2023)
Получение нового наноколлоидного радиофармпрепарата на основе оксида алюминия; Известия Томского политехнического университета [Известия ТПУ]; Т. 323, № 3 : Химия
Foilsithe / Cruthaithe: (2013)
Foilsithe / Cruthaithe: (2013)
Радиохимический комплекс на основе меченных 99mТс антимикробных пептидов UBI29-41 и UBI18-35 для дифференциальной диагностики септического воспаления костей конечностей; Бюллетень экспериментальной биологии и медицины; Т. 170, № 10
Foilsithe / Cruthaithe: (2020)
Foilsithe / Cruthaithe: (2020)
Cross section of the 96Zr(α,n)99Mo reaction induced by α-particles beams on natZr targets; Applied Radiation and Isotopes; Vol. 166
Foilsithe / Cruthaithe: (2020)
Foilsithe / Cruthaithe: (2020)
Antigen Processing Methods and Protocols /
Foilsithe / Cruthaithe: (2019)
Foilsithe / Cruthaithe: (2019)
Antigen Processing Methods and Protocols /
Foilsithe / Cruthaithe: (2013)
Foilsithe / Cruthaithe: (2013)
Largest consistent subsets in interlaboratory comparisons: preference aggregation approach; 14th Joint International IMEKO TC1, TC7, TC13 Symposium on Intelligent Quality Measurements - Theory, Education and Training, August 31 - September 2, 2011, Jena, Germany
de réir: Muravyov (Murav’ev) S. V. Sergey Vasilyevich
Foilsithe / Cruthaithe: (2011)
de réir: Muravyov (Murav’ev) S. V. Sergey Vasilyevich
Foilsithe / Cruthaithe: (2011)
Phase I Clinical Trial Using [99mTc]Tc-1-thio-D-glucose for Diagnosis of Lymphoma Patients; Pharmaceutics; Vol. 14, iss. 6
Foilsithe / Cruthaithe: (2022)
Foilsithe / Cruthaithe: (2022)
The future of PSMA-targeting 64Cu-radiopharmaceuticals: a short review of recent preclinical research; Научная инициатива иностранных студентов и аспирантов
de réir: Lutfi Aditya Hasnowo
Foilsithe / Cruthaithe: (2022)
de réir: Lutfi Aditya Hasnowo
Foilsithe / Cruthaithe: (2022)
Изучение адсорбции 99mTC на оксиде алюминия; Радиохимия; № 5
Foilsithe / Cruthaithe: (2011)
Foilsithe / Cruthaithe: (2011)
Antigen Processing and Presentation Protocols
Foilsithe / Cruthaithe: (2001)
Foilsithe / Cruthaithe: (2001)
Оценка специфичности связывания [177Lu] Lu-BQ7876 c PSMA-экспрессирующей клеточной линией PC3-pip in vitro; Химия и химическая технология в XXI веке; Т. 1
de réir: Сейтова К.
Foilsithe / Cruthaithe: (2022)
de réir: Сейтова К.
Foilsithe / Cruthaithe: (2022)
Prostate Cancer Methods and Protocols /
Foilsithe / Cruthaithe: (2018)
Foilsithe / Cruthaithe: (2018)
Adsorption of 99mTc on aluminum oxide; Radiochemistry; Vol. 53, iss. 5
Foilsithe / Cruthaithe: (2011)
Foilsithe / Cruthaithe: (2011)
On the characteristic voltage of high-Tc superconductors; Journal of Superconductivity; Vol. 4, iss. 3
de réir: Vasiliev B. V.
Foilsithe / Cruthaithe: (1991)
de réir: Vasiliev B. V.
Foilsithe / Cruthaithe: (1991)
Comparative Preclinical Evaluation of HYNIC-Modified Designed Ankyrin Repeat Proteins G3 for the 99mTc-Based Imaging of HER2-Expressing Malignant Tumors; Molecular Pharmaceutics; Vol. 21, iss. 4
Foilsithe / Cruthaithe: (2024)
Foilsithe / Cruthaithe: (2024)
Míreanna comhchosúla
-
Reduction of Negative Charge in Mercaptoacetyl-Based Chelators Influences the Biodistribution of Prostate-Specific Membrane Antigen-Targeting Pseudopeptides Labeled with Technetium-99m; ACS Pharmacology & Translational Science; Vol. 8, iss. 10
Foilsithe / Cruthaithe: (2025) -
Synthesis and Preclinical Evaluation of Urea-Based Prostate-Specific Membrane Antigen-Targeted Conjugates Labeled with 177Lu; ACS Pharmacology & Translational Science; Vol. 7, iss. 5
Foilsithe / Cruthaithe: (2024) -
Single-Photon Emission Computer Tomography Imaging of Prostate-Specific Membrane Antigen (PSMA) Expression in Prostate Cancer Patients Using a Novel Peptide-Based Probe [99mTc]Tc-BQ0413 with Picomolar Affinity to PSMA: A Phase I/II Clinical Study; ACS Pharmacology & Translational Science; Vol. 8, iss. 3
Foilsithe / Cruthaithe: (2025) -
Synthesis, 123I-Radiolabeling Optimization, and Initial Preclinical Evaluation of Novel Urea-Based PSMA Inhibitors with a Tributylstannyl Prosthetic Group in Their Structures; International Journal of Molecular Sciences; Vol. 24, iss. 15
Foilsithe / Cruthaithe: (2023) -
Heterodimeric Radiotracer Targeting PSMA and GRPR for Imaging of Prostate Cancer—Optimization of the Affinity towards PSMA by Linker Modification in Murine Model; Pharmaceutics; Vol. 12, iss. 7
Foilsithe / Cruthaithe: (2020)